论文部分内容阅读
AIM To verify whether recurrence-free survival(RFS)surrogates overall survival(OS)in phaseⅢtrials for resectable colorectal liver metastases(CRLM).METHODS MEDLINE,EMBASE,and Scopus databases were consulted.Eligible studies were phaseⅢtrials testing any ty